Pulmonary delivery of insulin by dry powder inhaler formulations

Document Type : Original Article

Authors

1 Pharmaceutical Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

3 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

4 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

10.22038/ijbms.2025.83954.18168

Abstract

Objective(s): Insulin therapy is critical in diabetic patients for controlling blood glucose levels. In recent years, pulmonary insulin delivery has emerged as an alternative approach for overcoming the therapeutic disadvantages of subcutaneous insulin administration, such as pain, infection risk, and needle phobia. To develop the pulmonary insulin formulation, five insulin-containing dry powder inhalers (DPIs) with different excipients were tested in diabetic rats.
Materials and Methods: Formulations were inoculated endotracheally to diabetic rats induced by streptozotocin. Insulin and glucose assays were performed on blood samples taken from the carotid artery at different intervals, including baseline and 1–4 hr after insulin administration. 
Results: The results illustrated that five formulations (F1-F5) could gradually increase the plasma insulin level during time points of the study. The first and third formulations comprising insulin, mannitol, and sodium citrate in the absence (F1) or presence of sodium alginate (F3) also declined plasma glucose levels in animals. 
Conclusion: The results confirmed that the pulmonary formulations could deliver and release insulin molecules in a good manner, and the biological activity of the two formulations, including F1 and F3, is acceptable and comparable to the subcutaneous insulin. Our findings support that the mentioned DPI products could have therapeutic potential as an alternative to subcutaneous insulin. Further investigations are needed to prove the capability of F1 and F3 spray-dried products to treat diabetic individuals. 

Keywords

Main Subjects

References

1. Henkin RI. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: Mechanisms of action. Nutrition 2010; 26:33-39.
2. Khodaverdi E, Heidari Z, Tabassi SA, Tafaghodi M, Alibolandi M, Tekie FS, et al. Injectable supramolecular hydrogel from insulin-loaded triblock PCL-PEG-PCL copolymer and γ-cyclodextrin with sustained-release property. AAPS PharmSciTech 2015; 16:140-149.
3. Shah RB, Patel M, Maahs DM, Shah VN. Insulin delivery methods: Past, present and future. Int J Pharm Investig 2016; 6:1-9.
4. Shen YB, Du Z, Tang C, Guan YX, Yao SJ. Formulation of insulin-loaded N-trimethyl chitosan microparticles with improved efficacy for inhalation by supercritical fluid assisted atomization. Int J Pharm 2016; 505:223-233.
5. Liu H, Shan X, Yu J, Li X, Hu L. Recent advances in inhaled formulations and pulmonary insulin delivery systems. Curr Pharm Biotechnol 2020; 21:180-193.
6. Okamoto H, Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev 2008; 60:433-446.
7. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther 2007; 9 Suppl 1:S65-S72.
8. Neumiller JJ, Campbell RK, Wood LD. A review of inhaled technosphere insulin. Ann Pharmacother 2010; 44:1231-1239.
9. Mitta SG, Tanvi S, Bhargavi U, Ruchitha V. An Overview on Pulmonary Insulin. Glob Acad J Pharm Drug Res 2024; 6:12-19.
10. Karmakar S, Bhowmik M, Laha B, Manna S. Recent advancements on novel approaches of insulin delivery. Med Nov Technol Devices 2023; 19:100253.
11. Razavi Rohani SS, Abnous K, Tafaghodi M. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients. Int J Pharm 2014; 465:464-478.
12. Sou T, Kaminskas LM, Nguyen T-H, Carlberg R, McIntosh MP, Morton DA. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur J Pharm Biopharm 2013; 83:234-243.
13. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392:1-19.
14. Karimi M, Kamali H, Mohammadi M, Tafaghodi M. Evaluation of various techniques for production of inhalable dry powders for pulmonary delivery of peptide and protein. J Drug Deliv Sci Technol 2022; 69:103186.
15. Zillen D, Beugeling M, Hinrichs WL, Frijlink HW, Grasmeijer F. Natural and bioinspired excipients for dry powder inhalation formulations. Curr Opin Colloid Interface Sci 2021; 56:101497.
16. Shetty N, Cipolla D, Park H, Zhou QT. Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv 2020; 17:77-96.
17. Valente SA, Silva LM, Lopes GR, Sarmento B, Coimbra MA, Passos CP. Polysaccharide-based formulations as potential carriers for pulmonary delivery–a review of their properties and fates. Carbohydr Polym  2022; 277:118784.
18. Li H-Y. Alginate-based inhalable particles for controlled pulmonary drug delivery. Alginate Biomaterial: Drug Delivery Strategies and Biomedical Engineering: Springer; 2023. p. 207-240.
19. Shen Y-B, Du Z, Tang C, Guan Y-X, Yao S-J. Formulation of insulin-loaded N-trimethyl chitosan microparticles with improved efficacy for inhalation by supercritical fluid assisted atomization. Int J Pharm 2016; 505:223-233.
20. Kantak MN, Bharate SS. Analysis of clinical trials on biomaterial and therapeutic applications of chitosan: A review. Carbohydrate Polymers 2022; 278:118999.
21. Ye Y, Ma Y, Zhu J. The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders? Int J Pharm 2022; 614:121457.
22. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002; 103:311-321.
23. Rösen P, Ballhausen T, Stockklauser K. Impairment of endothelium dependent relaxation in the diabetic rat heart: mechanisms and implications. Diabetes Res Clin Pract 1996; 31 Suppl:S143-155.
24. Brown RH, Walters DM, Greenberg RS, Mitzner W. A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice. J Appl Physiol (1985) 1999; 87:2362-2365.
25. Chukwuma CI, Matsabisa MG, Erukainure OL, Ibeji CU, Islam MS. D-mannitol modulates glucose uptake ex vivo; suppresses intestinal glucose absorption in normal and type 2 diabetic rats. Food Bioscience 2019; 29:30-36.
26. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357:331-335.
27. Silva CM, Ribeiro AJ, Figueiredo IV, Goncalves AR, Veiga F. Alginate microspheres prepared by internal gelation: development and effect on insulin stability. Int J Pharm 2006; 311:1-10.
28. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007; 24:2198-2206.
29. Jadach B, Świetlik W, Froelich A. Sodium alginate as a pharmaceutical excipient: novel applications of a well-known polymer. J Pharm Sci 2022; 111:1250-1261.
30. Bácskay I, Papp B, Pártos P, Budai I, Pető Á, Fehér P, et al. Formulation and evaluation of insulin-loaded sodium-alginate microparticles for oral administration. Pharmaceutics 2023; 16:46-61.
31. Chai Z, Dong H, Sun X, Fan Y, Wang Y, Huang F. Development of glucose oxidase-immobilized alginate nanoparticles for enhanced glucose-triggered insulin delivery in diabetic mice. Int J Biol Macromol 2020; 159:640-647.
32. Kimura Y, Watanabe K, Okuda H. Effects of soluble sodium alginate on cholesterol excretion and glucose tolerance in rats. J Ethnopharmacol 1996; 54:47-54.
33. Husni A, Pawestri S, Isnansetyo A. Blood glucose level and lipid profile of alloxan–induced diabetic rats treated with na-alginate from seaweed turbinaria ornata (Turner). J Agardh Jurnal Teknologi 2016; 78:7-14.
34. Shaikh MAJ, Gupta G, Afzal O, Gupta MM, Goyal A, Altamimi ASA, et al. Sodium alginate-based drug delivery for diabetes management: A review. Int J Biol Macromol 2023; 236:123986.
35. Dunne MJ, Yule DI, Gallacher DV, Petersen OH. Effects of alanine on insulin-secreting cells: Patch-clamp and single cell intracellular Ca2+ measurements. Biochim Biophys Acta 1990; 1055:157-164.
36. Sann L, Ruitton A, Mathieu M, Bourgeois J, Genoud J. Effect of intravenous L-alanine administration on plasma glucose, insulin and glucagon, blood pyruvate, lactate and beta-hydroxybutyrate concentrations in newborn infants. Study in term and preterm newborn infants. Acta Paediatr Scand 1978; 67:297-302.
37. Chashmniam S, Madani NH, Ghoochani BF, Safari-Alighiarloo
N, Khamseh ME. The metabolome profiling of obese and non-obese individuals: Metabolically healthy obese and unhealthy non-obese paradox. Iran J Basic Med Sci 2020; 23:186-194.
38. Porcellati F, Pampanelli S, Rossetti P, Busciantella Ricci N, Marzotti S, Lucidi P, et al. Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. Diabetologia 2007; 50:422-430.
39. van Sloun B, Goossens GH, Erdos B, Lenz M, van Riel N, Arts IC. The impact of amino acids on postprandial glucose and insulin kinetics in humans: A quantitative overview. Nutrients 2020; 12:3211-3233.
40. McClenaghan NH, Scullion SM, Mion B, Hewage C, Malthouse JPG, Flatt PR, et al. Prolonged L-alanine exposure induces changes in metabolism, Ca2+ handling, and desensitization of insulin secretion in clonal pancreatic β-cells. Clin Sci 2009; 116:341-351.
41. Genuth SM, Castro J. Effect of oral alanine on blood beta-hydroxybutyrate and plasma glucose, insulin, free fatty acids, and growth hormone in normal and diabetic subjects. Metabolism 1974; 23:375-386.
42. Asano T, Ninomiya H, Kan K, Yamamoto T, Okumura M. Plasma glucagon response to intravenous alanine in obese and non-obese subjects. Endocrinol Jpn 1989; 36:767-773.
43. Marttin E, Verhoef JC, Romeijn SG, Merkus FW. Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm Res 1995; 12:1151-1157.
44. Merkus F, Schipper N, Hermens W, Romeijn S, Verhoef J. Absorption enhancers in nasal drug delivery: Efficacy and safety. J Control Release 1993; 24:201-208.
45. Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release 2009; 137:104-109.
46. Chono S, Togami K, Itagaki S. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary absorption of encapsulated insulin compared with co-administered insulin. Drug Dev Ind Pharm 2017; 43:1892-1898.
47. Mitra R, Pezron I, Li Y, Mitra AK. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int J Pharm 2001; 217:25-31.
48. Wiessner JH, Hwang KJ. Binding of insulin to the external surface of liposomes: Effect of surface curvature, temperature, and lipid composition. Biochim Biophys Acta1982; 689:490-498.
49. Weijers RN. Lipid composition of cell membranes and its relevance in type 2 diabetes mellitus. Curr Diabetes Rev 2012; 8:390-400.
50. Priyanka D, Prashanth KH, Tharanathan R. A review on potential antidiabetic mechanisms of chitosan and its derivatives. Carbohydr Polym Technol Appl 2022; 3:100188.
51. Liao Z, Zhang J, Liu B, Yan T, Xu F, Xiao F, et al. Polysaccharide from okra (Abelmoschus esculentus (L.) Moench) improves antioxidant capacity via PI3K/AKT pathways and Nrf2 translocation in a type 2 diabetes model. Molecules 2019; 24:1906.
52. Kondo Y, Nakatani A, Hayashi K, Ito M. Low molecular weight chitosan prevents the progression of low dose streptozotocin-induced slowly progressive diabetes mellitus in mice. Biol Pharm Bull 2000; 23:1458-1464.
53. Hayashi K, Ito M. Antidiabetic action of low molecular weight chitosan in genetically obese diabetic KK-Ay mice. Biol Pharm Bull 2002; 25:188-192.
54. Yao HT, Huang SY, Chiang MT. A comparative study on hypoglycemic and hypocholesterolemic effects of high and low molecular weight chitosan in streptozotocin-induced diabetic rats. Food Chem Toxicol 2008; 46:1525-1534.
55. Chang H-P, Yao H-T, Chiang M-T. Effects of high and low molecular weight chitosan on plasma cholesterol, glucose and adipocytokines in diabetic rats induced by streptozotocin and nicotinamide. J Food Drug Anal 2012; 20:661-667.
 
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 7
July 2025
Pages 873-879

Files

Share

How to cite

Statistics